MONARCH 2: Abemaciclib with Fulvestrant in HR+/HER2-Positive Early Breast Cancer

Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib with fulvestrant in patients with HR+/HER2- Advanced Breast Cancer who have progressed on endocrine therapy.... Author: moasc Added: 08/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts